My site

− Presentations Include New Data from the TAK-861-2001 Phase 2b Trial in Narcolepsy Type 1 Highlighting Impact on Daily Functioning Including Cognition and Sleep Quality

− Data from Long-Term Extension Study will also be Presented

− Phase 3 Trial of an Orexin Agonist for Narcolepsy Type 1 Now Enrolling Patients Globally

(BUSINESS WIRE) -- Takeda (TSE:4502/NYSE:TAK) will present additional data from the Phase 2b trials (TAK-861-2001,TAK-861-2002) and long-term extension (LTE) study (TAK-861-2003) of TAK-861 in narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) at Sleep Europe 2024, the 27th Congress of the European Sleep Research Society (ESRS), being held September 24-27, 2024 in Seville, Spain. TAK-861 is an investigational oral orexin receptor 2 (OX2R) selective-agonist designed to address the orexin deficiency in NT1 by selectively stimulating the orexin receptor 2. TAK-861 has the potential to be the first tre ... Read more »

Dubai, United Arab Emirates - Thursday, 19. September 2024 AETOSWire  

Compiled with contributions from international and UAE-based experts, the report focuses on innovative strategies to empower and support youth and future generations.

The Dubai Future Foundation (DFF) has launched a special edition of its ‘Global 50’ report, exploring innovative solutions that empower youth and future generations.

Released ahead of the 2024 United Nations' 'Summit of the Future', the ‘Global 50: Future Opportunities’ report complements the forthcoming UN 'Pact for the Future', ‘Declaration on Future Generations’ and ‘Global Digital Compact’, which focus on addressing challenges and opportunities of today and for years to come.

This edition features insights from both international and UAE experts, spotlighting opportunities that drive innovation, address global challenges, and s ... Read more »